TD Cowen Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities researchers at TD Cowen from a “buy” rating to a “hold” rating in a research note issued on Tuesday. They currently have a $42.00 price objective on the stock. TD Cowen’s target price indicates a potential upside of 5.60% from the stock’s previous close.

Several other brokerages have also recently commented on NVO. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $39.77 on Tuesday. The firm’s 50-day simple moving average is $51.18 and its two-hundred day simple moving average is $52.24. The firm has a market cap of $177.59 billion, a price-to-earnings ratio of 11.46 and a beta of 0.74. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently bought and sold shares of the business. Quotient Wealth Partners LLC grew its stake in Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares in the last quarter. Certuity LLC increased its stake in shares of Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares during the last quarter. Beacon Financial Group raised its holdings in Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the period. Oakworth Capital Inc. lifted its holdings in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the last quarter. Finally, True North Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after buying an additional 199 shares during the period. Institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo agreed to sell its branded GLP‑1 drugs (Wegovy and Ozempic) through Hims & Hers’ telehealth platform, ending the recent patent lawsuit — this gives Novo a direct digital channel to Hims’ large user base and removes a source of unregulated compounded competition. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Novo launched a share repurchase programme (part of up to DKK 15bn over 12 months), which supports the stock via buyback-driven EPS support and signals management confidence in cash generation. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Analysts note the deal helps Novo regain a controlled digital distribution route (access to millions of telehealth users) and preserves branded economics while curbing compounding competitors — a constructive repositioning if adoption through telehealth proves durable. Novo’s Quiet Comeback Begins
• Neutral Sentiment: Brokerage consensus remains cautious (consensus “Hold”); analysts are updating estimates for FY2026 and watching GLP‑1 pricing and volume trends — this tempers immediate upside from the Hims deal. Novo Nordisk A/S (NYSE:NVO) Given Consensus Recommendation of “Hold” by Brokerages
• Negative Sentiment: Market commentary highlights material recent share-price erosion (nearly $50bn in market cap loss in a month) as competitive pressure from rivals (e.g., Lilly) and potential price cuts across the GLP‑1 franchise weigh on growth expectations and valuation. NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.